Literature DB >> 27648014

Evaluation of Nephroprotective Efficacy of Hypoxic Preconditioning in Patients Undergoing Coronary Artery Bypass Surgery.

Zhaneta V Vesnina1, Yury B Lishmanov1, Ekaterina A Alexandrova2, Evgeniy A Nesterov3.   

Abstract

BACKGROUND: Nonpulsatile blood flow plays an important role in the pathogenesis of renal dysfunction in patients with extracorporeal circulation. In our opinion, hypoxic preconditioning (HP) can be used to protect kidneys from postsurgical dysfunction. The aim of this study was to evaluate nephroprotective efficacy of HP in myocardial revascularization with extracorporeal circulation.
METHODS: The randomized, controlled trial was performed in 63 patients undergoing coronary artery bypass grafting (CABG). Thirty-three patients were subjected to HP during CABG; 30 patients were included in the comparison group. All patients underwent dynamic renal scintigraphy with (99m)Тc-diethylenetriaminepentaacetic acid and were subjected to measuring the concentration of lipocalin in blood serum before and after CABG.
RESULTS: After CABG, the mean values of the total glomerular filtration rate (GFR) and GFR for each kidney significantly decreased only in patients of the comparison group. Significant increases in the concentration of serum neutrophil gelatinase-associated lipocalin occurred 5 h after surgery both in the group with HP (70.65 ± 46.71 to 127.58 ± 98.46 ng/ml) and in the comparison group (65.01 ± 38.64 to 171.65 ± 89.91 ng/ml). At the same time, the mean difference values between pre- and postoperative lipocalin levels were 56.94 ± 51.75 ng/ml in the study group and 106.64 ± 51.27 ng/ml in the comparison group; these differences were highly statistically significant (р = 0.004).
CONCLUSION: The results of our study showed that (i) HP exerts nephroprotection in patients undergoing on-pump CABG, and (ii) determination of the lipocalin-2 level can be used for early diagnosis of acute kidney injury in cardiac surgery patients.

Entities:  

Keywords:  Coronary artery bypass grafting; Dynamic renal scintigraphy; Hypoxic preconditioning; Neutrophil gelatinase-associated lipocalin

Year:  2016        PMID: 27648014      PMCID: PMC5020376          DOI: 10.1159/000446571

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  23 in total

1.  Ischaemic preconditioning has a beneficial effect on left ventricular haemodynamic function after a coronary artery biopass grafting operation.

Authors:  Z K Wu; M R Tarkka; E Pehkonen; L Kaukinen; E L Honkonen; S Kaukinen
Journal:  Scand Cardiovasc J       Date:  2000-06       Impact factor: 1.589

2.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.

Authors:  Jaya Mishra; Catherine Dent; Ridwan Tarabishi; Mark M Mitsnefes; Qing Ma; Caitlin Kelly; Stacey M Ruff; Kamyar Zahedi; Mingyuan Shao; Judy Bean; Kiyoshi Mori; Jonathan Barasch; Prasad Devarajan
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

Review 3.  Cardiopulmonary bypass and renal injury.

Authors:  Yasir Abu-Omar; Chandana Ratnatunga
Journal:  Perfusion       Date:  2006-07       Impact factor: 1.972

4.  Ischaemic preconditioning protects the rat kidney from reperfusion injury.

Authors:  N Toosy; E L McMorris; P A Grace; R T Mathie
Journal:  BJU Int       Date:  1999-09       Impact factor: 5.588

Review 5.  Acute kidney injury in cardiac surgery.

Authors:  Alan M Gaffney; Robert N Sladen
Journal:  Curr Opin Anaesthesiol       Date:  2015-02       Impact factor: 2.706

6.  Neutrophil gelatinase-associated lipocalin as a survival factor.

Authors:  Zhimin Tong; Xuli Wu; Dmitriy Ovcharenko; Jiuxiang Zhu; Ching-Shih Chen; James P Kehrer
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

7.  Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.

Authors:  K M Choi; J S Lee; E J Kim; S H Baik; H S Seo; D S Choi; D J Oh; C G Park
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

8.  Acute renal failure following cardiac surgery: incidence, outcomes and risk factors.

Authors:  G J Mangos; M A Brown; W Y Chan; D Horton; P Trew; J A Whitworth
Journal:  Aust N Z J Med       Date:  1995-08

9.  Renal ischemic preconditioning improves recovery of kidney function and decreases alpha-smooth muscle actin expression in a rat model.

Authors:  Marc Olivier Timsit; Rudy Gadet; Hassen Ben Abdennebi; Ricardo Codas; Palmina Petruzzo; Lionel Badet
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

10.  Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study.

Authors:  Catherine L Dent; Qing Ma; Sudha Dastrala; Michael Bennett; Mark M Mitsnefes; Jonathan Barasch; Prasad Devarajan
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  3 in total

1.  The Integrated RNA Landscape of Renal Preconditioning against Ischemia-Reperfusion Injury.

Authors:  Marc Johnsen; Torsten Kubacki; Assa Yeroslaviz; Martin Richard Späth; Jannis Mörsdorf; Heike Göbel; Katrin Bohl; Michael Ignarski; Caroline Meharg; Bianca Habermann; Janine Altmüller; Andreas Beyer; Thomas Benzing; Bernhard Schermer; Volker Burst; Roman-Ulrich Müller
Journal:  J Am Soc Nephrol       Date:  2020-02-28       Impact factor: 10.121

2.  Activation of hypoxia-sensing pathways promotes renal ischemic preconditioning following myocardial infarction.

Authors:  Andrew S Terker; Kensuke Sasaki; Juan Pablo Arroyo; Aolei Niu; Suwan Wang; Xiaofeng Fan; Yahua Zhang; Sochinweichi Nwosisi; Ming-Zhi Zhang; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-01

3.  Hypoxia preconditioning attenuates lung injury after thoracoscopic lobectomy in patients with lung cancer: a prospective randomized controlled trial.

Authors:  Wenjing Zhang; Mo Chen; Hongbin Li; Jia Yuan; Jingjing Li; Feixiang Wu; Yan Zhang
Journal:  BMC Anesthesiol       Date:  2019-11-11       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.